Engineering Salmonella as intracellular factory for effective killing of tumour cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Camacho, Eva María ^a   Mesa Pereira, Beatriz ^a   Medina, Carlos ^a   Flores, Amando ^a   Santero, Eduardo ^a  

^a Departamento de Biología Molecular e Ingeniería Bioquímica   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4-EPIANHYDROTETRACYCLINE; BACTERIAL PROTEIN; GLYCOPROTEIN; GREEN FLUORESCENT PROTEIN; RECOMBINANT PROTEIN; SALICYLIC ACID DERIVATIVE; SIFA PROTEIN, SALMONELLA; TETRACYCLINE DERIVATIVE;

APOPTOSIS; BIOLOGICAL THERAPY; CYTOSOL; DRUG EFFECTS; GENETIC ENGINEERING; GENETICS; HELA CELL LINE; HUMAN; MCF-7 CELL LINE; METABOLISM; PROCEDURES; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BACTERIAL PROTEINS; CELL- AND TISSUE-BASED THERAPY; CYTOSOL; GENES, P53; GENETIC ENGINEERING; GLYCOPROTEINS; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; MCF-7 CELLS; RECOMBINANT PROTEINS; SALICYLATES; SALMONELLA TYPHIMURIUM; TETRACYCLINES;

EID: 84979879814     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30591     Document Type: Article

References (59)

1. Pinero-Lambea, C., Ruano-Gallego, D. & Fernandez, L. A. Engineered bacteria as therapeutic agents. Curr. Opin. Biotechnol. 35, 94-102, doi: 10.1016/j.copbio.2015.05.004 (2015).
2. Forbes, N. S. Engineering the perfect (bacterial) cancer therapy. Nature reviews. Cancer 10, 785-794, doi: 10.1038/nrc2934 (2010).
3. Chorobik, P., Czaplicki, D., Ossysek, K. & Bereta, J. Salmonella and cancer: from pathogens to therapeutics. Acta Biochim. Pol. 60, 285-297 (2013).
4. Bernardes, N., Chakrabarty, A. M. & Fialho, A. M. Engineering of bacterial strains and their products for cancer therapy. Appl. Microbiol. Biotechnol. 97, 5189-5199, doi: 10.1007/s00253-013-4926-6 (2013).
5. Pawelek, J. M., Low, K. B. & Bermudes, D. Tumor-Targeted Salmonella as a novel anticancer vector. Cancer Res. 57, 4537-4544 (1997).
6. Saltzman, D. A. et al. Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: A novel anti-Tumor agent. Cancer Biother. Radiopharm. 11, 145-153 (1996).
7. Yam, C. et al. Monotherapy with a tumor-Targeting mutant of S.Typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J. Surg. Res. 164, 248-255, doi: 10.1016/j.jss.2009.02.023 (2010).
8. Yu, H. Bacteria-mediated disease therapy. Appl. Microbiol. Biotechnol. 92, 1107-1113, doi: 10.1007/s00253-011-3648-x (2011).
9. Lahiri, A., Iyer, N., Das, P. & Chakravortty, D. Visiting the cell biology of Salmonella infection. Microbes Infect. 12, 809-818 (2010).
10. Royo, J. L. et al. In vivo gene regulation in Salmonella spp. by a salicylate-dependent control circuit. Nat. Methods 4, 937-942 (2007).
11. Mesa-Pereira, B., Medina, C., Camacho, E. M., Flores, A. & Santero, E. Improved cytotoxic effects of Salmonella-producing cytosine deaminase in tumour cells. Microb. Biotechnol. 8, 169-176, doi: 10.1111/1751-7915.12153 (2015).
12. Mesa-Pereira, B., Medina, C., Camacho, E. M., Flores, A. & Santero, E. Novel tools to analyze the function of Salmonella effectors show that SvpB ectopic expression induces cell cycle arrest in tumor cells. PLoS One 8, e78458, doi: 10.1371/journal.pone.0078458 (2013).
13. Loeffler, M., LeNegrate, G., Krajewska, M. & Reed, J. C. Inhibition of tumor growth using Salmonella expressing Fas ligand. J. Natl. Cancer Inst. 100, 1113-1116, doi: 10.1093/jnci/djn205 (2008).
14. Theys, J. et al. Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha. Appl. Environ. Microbiol. 65, 4295-4300 (1999).
15. Nuyts, S. et al. Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation. Gene Ther. 8, 1197-1201, doi: 10.1038/sj.gt.3301499 (2001).
16. Valdivia, R. H., Hromockyj, A. E., Monack, D., Ramakrishnan, L. & Falkow, S. Applications for green fluorescent protein (GFP) in the study of host-pathogen interactions. Gene 173, 47-52 (1996).
17. Ruano-Gallego, D., Alvarez, B. & Fernandez, L. A. Engineering the Controlled Assembly of Filamentous Injectisomes in E. coli K-12 for Protein Translocation into Mammalian Cells. ACS Synth. Biol. 4, 1030-1041, doi: 10.1021/acssynbio.5b00080 (2015).
18. Jia, J. et al. Bacterial delivery of TALEN proteins for human genome editing. PLoS One 9, e91547, doi: 10.1371/journal.pone.0091547 (2014).
19. Le Gouellec, A. et al. A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy. Mol. Ther. 21, 1076-1086, doi: 10.1038/mt.2013.41 (2013).
20. Panthel, K., Meinel, K. M., Sevil Domenech, V. E., Trulzsch, K. & Russmann, H. Salmonella type III-mediated heterologous antigen delivery: A versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors. Int. J. Med. Microbiol. 298, 99-103, doi: 10.1016/j.ijmm.2007.07.002 (2008).
21. Epaulard, O. et al. Anti-Tumor immunotherapy via antigen delivery from a live attenuated genetically engineered Pseudomonas aeruginosa type III secretion system-based vector. Mol. Ther. 14, 656-661, doi: 10.1016/j.ymthe.2006.06.011 (2006).
22. Fu, W. et al. Synergistic antitumor efficacy of suicide/ePNP gene and 6-methylpurine 2′-deoxyriboside via Salmonella against murine tumors. Cancer Gene. Ther. 15, 474-484, doi: 10.1038/cgt.2008.19 (2008).
23. Lee, C. H., Wu, C. L. & Shiau, A. L. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther. 12, 175-184, doi: 10.1038/sj.cgt.7700777 (2005).
24. Varkouhi, A. K., Scholte, M., Storm, G. & Haisma, H. J. Endosomal escape pathways for delivery of biologicals. J. Control Release 151, 220-228, doi: 10.1016/j.jconrel.2010.11.004 (2011).
25. Guo, H. et al. Targeting tumor gene by shRNA-expressing Salmonella-mediated RNAi. Gene Ther. 18, 95-105, doi: 10.1038/gt.2010.112 (2011).
26. Xiang, S., Fruehauf, J. & Li, C. J. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat. Biotechnol. 24, 697-702, doi: 10.1038/nbt1211 (2006).
27. Ahmed, O., Kruhn, A. & Lage, H. Delivery of siRNAs to cancer cells via bacteria. Methods Mol. Biol. 1218, 117-129, doi: 10.1007/978-1-4939-1538-5-7 (2015).
28. Jain, V. & Mekalanos, J. J. Use of lambda phage S and R gene products in an inducible lysis system for Vibrio cholerae-And Salmonella enterica serovar typhimurium-based DNA vaccine delivery systems. Infect. Immun. 68, 986-989 (2000).
29. Miksch, G., Fiedler, E., Dobrowolski, P. & Friehs, K. The kil gene of the ColE1 plasmid of Escherichia coli controlled by a growthphase-dependent promoter mediates the secretion of a heterologous periplasmic protein during the stationary phase. Arch. Microbiol. 167, 143-150 (1997).
30. Jeong, J. H. et al. Anti-Tumoral effect of the mitochondrial target domain of Noxa delivered by an engineered Salmonella typhimurium. PLoS One 9, e80050, doi: 10.1371/journal.pone.0080050 (2014).
31. Gutnick, D., Calvo, J. M., Klopotowski, T. & Ames, B. N. Compounds which serve as the sole source of carbon or nitrogen for Salmonella typhimurium LT-2. J. Bacteriol. 100, 215-219 (1969).
32. Gossen, M. & Bujard, H. Anhydrotetracycline, a novel effector for tetracycline controlled gene expression systems in eukaryotic cells. Nucleic Acids Res. 21, 4411-4412 (1993).
33. Medina, C., Camacho, E. M., Flores, A., Mesa-Pereira, B. & Santero, E. Improved expression systems for regulated expression in Salmonella infecting eukaryotic cells. PloS one 6, e23055, doi: 10.1371/journal.pone.0023055 (2011).
34. Cebolla, A., Royo, J. L., De Lorenzo, V. & Santero, E. Improvement of recombinant protein yield by a combination of transcriptional amplification and stabilization of gene expression. Appl. Environ. Microbiol. 68, 5034-5041 (2002).
35. Beuzon, C. R. et al. Salmonella maintains the integrity of its intracellular vacuole through the action of SifA. The EMBO journal 19, 3235-3249, doi: 10.1093/emboj/19.13.3235 (2000).
36. Farnebo, M., Bykov, V. J. & Wiman, K. G. The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer. Biochem. Biophys. Res. Commun. 396, 85-89, doi: 10.1016/j.bbrc.2010.02.152 (2010).
37. Muller, P. A. & Vousden, K. H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25, 304-317, doi: 10.1016/j.ccr.2014.01.021 (2014).
38. Li, Y. et al. Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-Terminal peptide in human premalignant and malignant cells. Int. J. Cancer. 115, 55-64, doi: 10.1002/ijc.20838 (2005).
39. Young, R. Bacteriophage lysis: mechanism and regulation. Microbiol. Rev. 56, 430-481 (1992).
40. White, R. et al. Holin triggering in real time. Proc. Natl. Acad. Sci. USA 108, 798-803, doi: 10.1073/pnas.1011921108 (2011).
41. Berry, J., Rajaure, M., Pang, T. & Young, R. The spanin complex is essential for lambda lysis. J. Bacteriol. 194, 5667-5674, doi: 10.1128/JB.01245-12 (2012).
42. Degenkolb, J., Takahashi, M., Ellestad, G. A. & Hillen, W. Structural requirements of tetracycline-Tet repressor interaction: determination of equilibrium binding constants for tetracycline analogs with the Tet repressor. Antimicrob. Agents Chemother. 35, 1591-1595 (1991).
43. Shaner, N. C. et al. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat. Biotechnol. 22, 1567-1572, doi: 10.1038/nbt1037 (2004).
44. Selivanova, G. et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-Terminal domain. Nat. Med. 3, 632-638 (1997).
45. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F. & Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139, 271-279 (1991).
46. Williams, K. J., Joyce, G. & Robertson, B. D. Improved mycobacterial tetracycline inducible vectors. Plasmid 64, 69-73, doi: 10.1016/j.plasmid.2010.04.003 (2010).
47. Hennekens, C. H. Update on aspirin in the treatment and prevention of cardiovascular disease. Am. J. Manag. Care 8, S691-S700 (2002).
48. Weissmann, G. Aspirin. Sci. Am. 264, 84-90 (1991).
49. Kim, A. L. et al. Conformational and molecular basis for induction of apoptosis by a p53 C-Terminal peptide in human cancer cells. J. Biol. Chem. 274, 34924-34931 (1999).
50. Thundimadathil, J. Cancer treatment using peptides: current therapies and future prospects. J. Amino Acids 2012, 967347, doi: 10.1155/2012/967347 (2012).
51. Zhao, M. et al. The milk-derived hexapeptide PGPIPN inhibits the invasion and migration of human ovarian cancer cells by regulating the expression of MTA1 and NM23H1 genes. Int. J. Oncol., doi: 10.3892/ijo.2016.3390 (2016).
52. Singh, S. et al. SATPdb: A database of structurally annotated therapeutic peptides. Nucleic Acids Res. 44, D1119-D1126, doi: 10.1093/nar/gkv1114 (2016).
53. Tutar, L., Tutar, E., Ozgur, A. & Tutar, Y. Therapeutic Targeting of microRNAs in Cancer: Future Perspectives. Drug Dev. Res. 76, 382-388, doi: 10.1002/ddr.21273 (2015).
54. Mishra, S., Yadav, T. & Rani, V. Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit. Rev. Oncol. Hematol. 98, 12-23, doi: 10.1016/j.critrevonc.2015.10.003 (2016).
55. Lee, C. H. Employment of Salmonella in Cancer Gene Therapy. Methods. Mol. Biol. 1409, 79-83, doi: 10.1007/978-1-4939-3515-4-8 (2016).
56. Schmieger, H. Phage P22-mutants with increased or decreased transduction abilities. Mol. Gen. Genet. 119, 75-88 (1972).
57. Sambrook, J., Fritsch, E. F. & Maniatis, T. Molecular cloning: A laboratory manual. (Cold Spring Harbor Laboratory Press, 2001).
58. Datsenko, K. A. & Wanner, B. L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. USA 97, 6640-6645, doi: 10.1073/pnas.120163297 (2000).
59. Senatus, P. B. et al. Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-Terminal peptide. Mol. Cancer. Ther. 5, 20-28, doi: 10.1158/1535-7163.MCT-05-0181 (2006).